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Conducted in Iran, participants included 69 adolescents with obsessive-compulsive disorder 
(OCD) who were on a stable selective serotonin reuptake inhibitor (SSRI) dose and were 
randomly assigned to one of three conditions: group acceptance and commitment therapy 
(ACT)+SSRI, group cognitive behavioral therapy (CBT)+SSRI, or continued SSRI treatment. 
Assessment occurred at pre-, post-treatment, and three-month follow-up and included the 
Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS), Children’s Depression 
Inventory (CDI), Avoidance and Fusion Questionnaire for Youth (AFQ-8), Valued Living 
Questionnaire (VLQ), and Child and Adolescent Mindfulness Measure (CAMM). ACT+SSRI 
and CBT+SSRI conditions demonstrated significant reductions in OCD severity that were 
maintained at follow-up compared to the continued SSRI condition. All conditions demonstrated 
significant reductions in depression that were maintained at follow-up. The ACT+SSRI 
condition demonstrated significant improvement in psychological flexibility, mindfulness, and 
valued living that were maintained at follow-up compared to the CBT+SSRI and continued SSRI 
conditions. Findings indicate that ACT+SSRI is comparably effective as CBT+SSRI at treating 
adolescent OCD. However, ACT+SSRI appears to differ from CBT+SSRI on changes in 
psychological flexibility, mindfulness, and valued living, indicating potential differences in 
mechanism of change.  
Keywords: Acceptance and Commitment Therapy, Cognitive-Behavioral Therapy, Adolescent, 
Obsessive-Compulsive Disorder, Randomized Controlled Trial  
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An Iranian Study of Group Acceptance and Commitment Therapy versus Group Cognitive 
Behavioral Therapy for Adolescents with Obsessive-Compulsive Disorder on an Optimal Dose 
of Selective Serotonin Reuptake Inhibitors 
Obsessive-compulsive disorder (OCD) is a chronic disorder involving recurrent and 
unwanted obsessions and corresponding repetitive compulsions aimed at managing the 
obsessions (Kaplan, 2016). One-third to one-half of adults with OCD had symptoms of OCD in 
childhood (Flament & Cohen, 2000). Prevalence of this disorder is between 0.06% and 2% 
among children and adolescents (Franklin, Foa, & March, 2003), and 2% to 3% in adults 
(Heyman et al., 2001; Rasmussen & Eisen, 1992). A systematic review of the prevalence of 
childhood OCD in Iran showed a range of 1% to 11.9%, which is notably higher than 
comparison countries (Zarafshan, Mohammadi, & Salmanian, 2015). The most common 
obsessions in adolescents are those related to contamination, harming a loved one or others, and 
symmetry, order, or exactness. The most common compulsions are washing, cleaning, checking, 
counting, ordering/arranging rituals, and touching (Kircanski, Peris, & Piacentini, 2011). In 
Islamic countries, due to the important role of cleanliness and washing in religious rituals for 
ablution (such as Vozo and Ghosl), washing compulsions are most common. Sexual and 
religious obsessions are more prevalent among adolescents than children and adults (Geller et al., 
2001).  
The comorbidity of OCD and other psychiatric disorders is high, with estimates ranging 
from 75% to 85% (Geller et al., 1998). Early onset OCD is comorbid with a wide range of 
psychiatric disorders such as anxiety and mood disorders, attention-deficit/hyperactivity disorder 
(ADHD), and tic disorders (Barrett, Healy-Farrell, Piacentini, & March, 2004). Clinical 
observations show considerable functional impairment in social, family, and academics in 
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adolescents with OCD (Storch et al., 2010; Valderhaug & Ivarsson, 2005). These findings 
suggest that OCD in youth is prevalent, has a poor prognosis without treatment, and negatively 
effects those diagnosed. Even though antidepressants are a first-line treatment in Iran, 
psychotherapy in general is accepted and often preferred. Thus, effective psychosocial treatments 
are needed. 
Cognitive-behavioral therapy (CBT) involving exposure and response prevention (ERP) 
alone or in combination with selective serotonin reuptake inhibitors (SSRIs) is the first line of 
treatment for OCD in children and adolescents (Geller & March, 2012). However, treatment is 
not effective for all. For example, a meta-analysis found response rates of 70% for CBT, 66% for 
CBT plus SSRI, and 49% for SSRI alone; but remission rates were lower at 53% for CBT, 49% 
for CBT plus SSRI, and 24% for SSRI alone (Öst, Riise, Wergeland, Hansen, & Kvale, 2016). 
The same meta-analysis found dropout rates of 12.7% for CBT and 23.5% for SSRI. Moreover, 
7.4% declined participation (Öst et al., 2016). Unwanted side-effects are a concern for SSRIs 
(Murphy, Segarra, Storch, & Goodman, 2008). Additionally, symptoms recur when the intake of 
medicine stops in 95% of patients (Catapano et al., 2006; Dougherty, Rauch, & Jenike, 2002). 
Thus, while excellent treatments for OCD exist, they are not effective for all and additional lines 
of inquiry are needed.  
Acceptance and Commitment Therapy (ACT) is beginning to show promise in the 
treatment of adult OCD (Bluett, Homan, Morrison, Levin, & Twohig, 2014; Rohani et al., 2018; 
Twohig & Levin, 2017). Currently, five randomized trials have been conducted with ACT for 
OCD (Rohani et al., 2018; Twohig & Levin, 2017), with averaged Yale-Brown Obsessive 
Compulsive Scale (Y-BOCS) scores of 24.2 (range 22-28) at pre-treatment, 13.2 (range 12-13) at 
post-treatment, and 10.7 (range 6-15) at follow-up. All of these studies utilized the same manual 
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that purposefully excluded in-session exposure exercises (Twohig et al., 2010). Exposure 
exercises are consistent with the ACT model (Twohig et al., 2015), but the original manual was 
written to test the effects of the ACT model without including techniques that were already 
known to be useful. A recent study also showed that ACT+ERP was equally effective to ERP 
with 70% and 68% responding in each condition (Twohig et al. 2018). Finally, while the work is 
limited, there is evidence that psychological flexibility, the target process of change in ACT, is 
present in OCD (Bluett et al., 2014) and predictive of changes in the treatment of OCD (Twohig, 
Vilardaga, Levin, & Hayes, 2015). There is growing evidence of the positive impact of 
willingness to experience obsessions being predictive of positive outcomes in traditional 
exposure therapy (Reid et al., 2017).   
Very few experimental studies have been conducted on the effect of ACT on adolescents 
(Halliburton & Cooper, 2015; Swain, Hancock, Dixon, & Bowman, 2015). ACT is a values-
based intervention drawing on metaphors and allegories that can be tailored to adolescents 
(Greco, Blackledge, Coyne, & Ehrenreich, 2005). Data in this area consists of two preliminary 
studies utilizing multiple baselines designs with children and adolescents with OCD (Armstrong, 
Morrison, & Twohig, 2013; Barney, Field, Morrison, & Twohig, 2017). Each study had three 
participants and used very similar protocols that were 8-10 sessions long. The amount of parental 
support varied by child age. One study was run with individuals below 12 years of age and one 
had adolescents 12 or older. Both studies had moderate effects with a general decrease in self-
reported obsessions and compulsions as well as validated measurements: Child Y-BOCS scores 
of 27 at pre-treatment and 14 at post-treatment for children, and 21 at pre-treatment, 15 at post-
treatment, and 11 at follow-up for the adolescents. While these initial findings are promising, 
more research is needed on the effects of ACT for adolescents with OCD.  
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In this study we examined the effectiveness of ACT for adolescents with OCD. In order 
to compare the effects of ACT to a gold-standard treatment, ACT was compared with traditional 
CBT. All participants in this study were on a stable dose of SSRI prior to starting ACT or CBT, 
thus a continued SSRI condition served as a control condition for effects beyond participating in 
this study. This is consistent with the heath practices of Iran where antidepressants are the first 
line of treatment. Finally, great emphasis was placed on assessments of processes of change to 
determine whether ACT+SSRI affected its proposed processes of change, and whether it did so 
greater than alternative conditions.  
Method 
Participants 
This research was approved by the Ethics Committee of Kashan University of Medical 
Sciences with the number of IR.KAUMS.REC.1395.124. Participants were referred by mental 
health professionals, school counselors, psychiatric clinics, and the specialized psychology clinic 
of Kargarnezhad Psychiatric Hospital in Kashan, Iran. All patients were on an optimal dose of a 
SSRI for at least 3 months, which included: clomipramine (Anafranil), fluoxetine (Prozac), 
fluvoxamine (Luvox), and sertraline (Zoloft). Optimal dose was achieved by starting patients at 
low doses (clomipramine 25 mg, fluoxetine 20 mg, fluvoxamine 50 mg, sertraline, 50 mg) and 
increasing every 3–4 days until maximum results were achieved with the fewest side effects. 
Patients stayed at their optimal doses throughout the study. The inclusion criteria required 
participants to: (a) meet DSM-5 criteria for OCD; (b) have a CYBOCS total score of 16 or 
higher; and (c) be between the ages of 12 and 18. The exclusion criteria required participants to: 
(a) not meet criteria for a comorbid psychiatric disorder with higher treatment priorities (e.g., 
psychosis, severe depression); (b) not have a neurodevelopmental disorder (e.g. autism-spectrum 
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disorders, mental disability, ADHD); (c) not meet criteria for drug abuse; (d) not have recently 
started a new psychotropic medication or planned on changing psychotropic medications during 
the course of the study; and (e) not have received a psychological intervention in the past year. 
All of the 92 referred participants were screened and assessed by a child and adolescent 
psychiatrist and a clinical psychologist, and 23 were excluded from the study. Of those excluded, 
16 did not meet inclusion or exclusion criteria, four declined participation in the research, and 
three were excluded for other reasons (e.g., did not attend the screening session or lived too far 
from the study location). The remaining 69 participants were randomly divided into ACT+SSRI 
(n = 22), CBT+SSRI (n = 22), or continued SSRI treatment (n = 25) conditions using a table of 
random numbers. See Figure 1 for a complete participant flowchart. Demographic information 
was collected during the intake interview and are displayed in Table 1. On average, participants 
were 14.96 years old (SD = 1.47, range = 12–18) and relatively evenly divided by sex (55.1% 
male). 
Therapists  
Therapists were two professional clinical psychologists, both of whom had been 
supervised and trained in ACT and CBT (two to four years of training in ACT and CBT). The 
therapists received weekly supervision from two clinical psychologists throughout the research 
study. All of the sessions were audio recorded and were reviewed weekly by the supervisors who 
assessed the internal consistency of the interventions. 
Method 
The participants were assigned to condition by a researcher unaware of the therapeutic 
interventions. The intervention conditions received one hour of ACT+SSRI or CBT+SSRI group 
therapy on a weekly basis. The ACT+SSRI condition consisted of a 10-session protocol while 
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the CBT+SSRI condition consisted of a 12-session protocol. Treatment was provided to 
participants at no cost. Participants were separated into male and female treatment groups as is 
common in treatment studies in Islamic cultures (i.e., schools are single sexed). Each group was 
composed of five to seven adolescents. All participants were assessed at pre-, post-treatment, and 
three months following post-treatment. Additional measures were used that will be reported in 
later publications. Evaluators were unaware of the treatment condition. Participants in the 
continued SSRI group were offered their choice of ACT or CBT treatment following the waitlist 
period. In addition, all participants were receiving SSRIs, that remained at a stable and 
unchanged dose, throughout the study. 
Interventions 
Cognitive-Behavioral Therapy. The CBT protocol was derived from the March and 
Mulle (1998) therapeutic manual for children and adolescents. The 12, one-hour sessions focused 
on psychoeducation, cognitive training, creating an exposure hierarchy and list of avoidance 
situations, ERP, and relapse prevention. Sessions 1 to 4 were dedicated to psychoeducation, 
which consisted of introducing the treatment, defining OCD, identifying OCD-related problems, 
cognitive training, and creation of an exposure hierarchy. Sessions 5 to 10 consisted of the 
implementation of ERP. Finally, sessions 11 and 12 were used to provide relapse prevention 
training and integrate lessons from the previous sessions. Each session involved reviewing the 
previous session, stating the goal for the session, and assigning homework between sessions. 
Cognitive restructuring was used as a means of coping with fear during sessions. Parents were 
invited to the final five minutes of each session. They received a report of participant progress, 
material covered in session, and were asked to restrict reassurance behavior in response to their 
child’s obsessions. 
ACT vs CBT vs Continued SSRI for Adolescent OCD   
 
9 
Acceptance and Commitment Therapy. The ACT protocol was derived from the 
Armstrong et al. (2013) therapeutic manual for adolescents. The ten, one-hour sessions focused 
on building rapport, psychoeducation, and training skills related to ACT processes. Sessions 1 to 
3 focused on processes known as creative hopelessness and control as the problem which 
examine the behaviors that the participant engages in to reduce their obsessions and the short- 
and long-term costs and benefits of doing so. Ultimately, the aim is for participants to recognize 
that many of their attempts to control unwanted internal events (e.g., thoughts, emotions, 
obsessions) are detrimental to their well-being in the long-term and to consider acceptance as an 
alternative to their control strategy. Sessions 4 and 5 focused on the processes of defusion and 
acceptance. Sessions 6 and 7 focused on examining and better establishing personal values and 
allowing unwanted internal events to be present while moving toward meaningful values-
constant behavior. Sessions 8 and 9 focused on present moment awareness and self-as-context 
processes. Finally, session 10 consisted of reviewing all previous sessions and relapse prevention 
training. Each session involved reviewing the previous session and setting goals to engage in 
values-consistent behavior between sessions (committed action). Parents were invited to the final 
five minutes of each session. They received a report of participant progress, material covered in 
session, and were asked to respond to reassurance seeking behaviors in ACT consistent ways. 
Measures 
Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS; Scahill et al., 1997). 
The CY-BOCS is a semi-structured interview used to assess OCD symptom severity. The scored 
portion used in the present study consists of 10 items rated on a five-point Likert scale. The sum 
of these items yields a total score (range = 0–40), with scores of 16 or more denoting clinically 
significant levels of OCD symptoms (Pediatric, 2004). Higher scores denote greater severity. 
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The CY-BOCS has demonstrated good internal consistency for the total score and obsession and 
compulsion subscales (αs = .87–.90, .80, and .82, respectively) in child and adolescent samples 
(Scahill et al., 1997; Storch et al., 2004). The Persian version of the CY-BOCS was used in the 
current study. The psychometric properties of this version have been validated in a study that is 
currently being prepared for publication. The CY-BOCS demonstrated good reliability in the 
current study (α = .86).  
Children’s Depression Inventory (CDI; Saylor, Finch, Spirito, & Bennett, 1984). The 
CDI is a 27-item self-report measure of depression. It is based on the Beck Depression Inventory 
(Beck, Steer, & Brown, 1996) and tailored for children and adolescents 7 to 17 years old 
(Kovacs, 1985). Items consist of three short phrases that describe thoughts and feelings during 
the past two weeks that participants are instructed to choose from. These items are scored from 0 
to 2 and summed into a total score (0–54). Higher scores denote greater levels of depression. 
Severity cutoff scores are as follows: 15–19 = mild, 20–24 = moderate, and 25 and greater = 
severe. The CDI has displayed good psychometric properties in clinical child and adolescent 
samples (Kovacs, 1985). The Persian version of the CDI was used in the current study and has 
demonstrated good test retest reliability (r = .82), internal consistency (α = .83), and convergent 
validity with the Beck Depression Inventory (Dehshiri, Najafi, Shikhi, & Habibi Askarabd, 
2009). The CDI demonstrated satisfactory internal consistency in the present study (α = .73). 
The Avoidance and Fusion Questionnaire for Youth (AFQ-Y8; Greco, Warren 
Lambert, & Ruth A Baer, 2008). The AFQ-Y8 is an eight-item self-report measure of 
psychological flexibility. Items are rated on a five-point Likert scale (0 = completely disagree to 
4 = completely agree) that are summed into a total score (0–32). Higher scores denote lower 
levels of psychological flexibility. The psychometric properties have been established in a 
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validation study (Laurie A. Greco, Warren Lambert, & Ruth A. Baer, 2008). The Persian version 
of AFQ-8 was used in the current study and has demonstrated the same single-factor model as 
the original English version (Shabani, Mohsenabadi, Zanjani, 2018). The AFQ-Y8 demonstrated 
adequate internal consistency in the present study (α =.77). 
The Valued-Living Questionnaire (VLQ; Wilson, Sandoz, Kitchens, & Roberts, 2010). 
The VLQ is a self-report measure of personal values and engagement in these values. It consists 
of two ten-item sections scored on a ten-point Likert scale. Part one measures the importance of 
ten broadly defined value domains (e.g., family relationships, employment, recreation). Part two 
measures the level in which one’s behaviors have been consistent with each value domain in the 
past week. A composite score is the calculated by multiplying the importance score by the 
consistency score for each value domain and then summing these products. The VLQ has 
demonstrated acceptable psychometric properties (Wilson, Sandoz, Kitchens, & Roberts, 2010). 
The Persian version of the VLQ was used in the current study. The psychometric properties of 
this version have been validated in a study that is currently being prepared for publication. The 
VLQ demonstrated good internal consistency in the present study (α = .87). 
Child and Adolescent Mindfulness Measure (CAMM; Greco, Baer, & Smith, 2011). 
The CAMM is a 10-item self-report measure of mindfulness. Items are rated on a five-point 
Likert scale (0 = Never True to 4 = Always True) that are summed into a total score (0–40). 
Higher scores denote greater levels of mindfulness. The Persian version of the CAMM was used 
in the current study. In a study that is currently being prepared for publication by authors, 
CAMM has demonstrated the same single-factor model as the original English version and 
satisfactory internal consistency (α = .73). The CAMM demonstrated satisfactory internal 
consistency in the present study (α = .73). 
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Therapeutic Alliance Scale for Children-Revised (TASC-R; Shirk & Saiz, 1992). The 
TASC-R is a 12-item self-report measure of therapeutic alliance for adolescents 12 to 18 years 
old. Items are rated on a four-point Likert scale (1 = Not at all to 4 = Very much) that are 
summed into a total score (12–48). Higher scores denote greater levels of therapeutic alliance. 
The TASC-R has displayed good psychometric properties (Creed & Kendall, 2005; Kazdin, 
Whitley, & Marciano, 2006). The TASC-R was translated into Persian for use in the current 
study. This version has not been validated as of yet. The TASC-R demonstrated good internal 
consistency in the present study (α = .80). 
The Credibility/Expectancy Questionnaire-Parent Version (CEQ-P; Nock, Ferriter, & 
Holmberg, 2007). The CEQ-P is a six-item self-report measure of beliefs about the credibility of 
therapies and expectations of therapy. The parent version was developed for parents of children 
and adolescents receiving therapy and is based on the original adult participant version 
(Borkovec & Nau, 1972; Devilly & Borkovec, 2000). Four items are rated on a nine-point Likert 
scale (1 = Not a lot of sense/no improvement; 9 = A lot of sense/very much improvement) and 
two items are scored on an 11-point scale (0% to 100%) that are recoded to a nine-point scale by 
converting values from 40 to 60 to a single value (i.e., 5). The scale includes two, three-item 
subscales (i.e., credibility and expectancy) that are individually summed (9–27). Higher scores 
denote greater levels of belief in credibility and beneficial expectations of therapy. The CEQ-P 
has displayed good psychometric properties (Nock et al., 2007). The CEQ-P was translated into 
Persian for use in the current study. This version has not been validated as of yet. 
Data Analysis 
Data were analyzed using SPSS 19 by a statistician who was blind to condition status. 
Multilevel modeling (MLM) was used to assess outcomes across pre-treatment, post-treatment, 
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and three-month follow-up in an intent-to-treat sample containing all participants. This method 
allows for all available data to be used to model change across the assessment periods, even 
when there is missing data. The three assessment periods were set to 0, 1, and 2, respectively as 
temporal variables. Time, condition, and a time × condition interaction were entered as fixed 
effects and participant ID was entered as a random effect, allowing for participant intercepts to 
vary by individual. 
Results 
Demographic and clinical characteristics of participants are displayed in Table 1. There 
were no significant difference between the groups at pre-treatment on any demographic or 
clinical characteristic (ps > .05), indicating sufficient randomization. Means and standard 
deviations for outcome variables at pre-treatment, post-treatment, and three-month follow-up by 
group are displayed in Table 2. At pre-treatment, participants reported clinically significant 
levels of OCD severity, mild depression, and typical levels of anxiety for a clinical sample. 
Results of the MLM analyses are displayed in Table 3. Slopes (change) from pre- to post-
treatment and from post-treatment to three-month follow-up are displayed for each condition 
with Holm-corrected p-values to correct for multiple tests. All reported effect sizes are Hedge’s g 
and were calculated from the means and standard deviations at each time-point, not the estimated 
marginal means computed by the MLM analyses. 
Therapist Adherence and Competence 
The Therapist Adherence Scale was developed for a prior study (Hancock et al., 2016) 
and used in the present study to measure therapist adherence to treatment protocol. A rater with a 
mastery of both treatment protocols measures the effective implementation of different 
components of the treatment protocols independent of the treatment groups. For the present study 
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the rating was based on 20 audiotapes selected randomly. This scale is rated on a five-point 
Likert scale (1 = Ineffective to 5 = Extremely effective). The average adherence rating was 4.34 
(0.33) in the CBT+ SSRI condition and 4.39 (0.36) in the ACT+ SSRI condition, which shows 
effective adherence in both conditions. There was no statistically significant difference between 
the conditions, t(18) = -0.32, p = .75.  
Therapist competence was assessed using the competence subscale of the ACT/CBT 
Therapist Adherence and Competence Scale (DUACRS; McGrath, Forman, & Herbert, 2012). 
The therapists’ competence was assessed for the following five skills: “knowledge of treatment," 
“skill in delivering treatment," “relationship with client," “appropriate application of treatment 
components within the context of session," and “overall performance." Each skill was rated 
based on the five-point Likert scale (1 = Poor to 5 = Excellent). The average competence rating 
was 4.09 (0.55) in the CBT+SSRI condition and 4.20 (0.65) in the ACT+SSRI condition, which 
shows high competence in both conditions. There was no statistically significant difference 
between the conditions t(18) = -0.40, p = .68. 
Therapeutic Alliance, Treatment Credibility, and Treatment Expectancy 
Therapeutic alliance was assessed following the second session of treatment using the 
TASC-R. The average therapeutic alliance rating was 33.74 (7.22) in the CBT+SSRI condition 
and 32.90 (7.28) in the ACT+SSRI condition, which is high therapeutic alliance in both 
conditions. There was no statistically significant difference between the conditions t(37) = -0.36, 
p = .72. 
Parent ratings of credibility and expectancy of therapy was assessed following the first 
session using the CEQ-P. The average credibility rating was 22.63 (4.27) for the CBT+SSRI 
condition and 23.09 (4.11) for the ACT+SSRI condition. The average expectancy rating was 
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20.72 (4.22) for the CBT+SSRI condition and 21.22 (4.10) for the ACT+SSRI condition. There 
were no statistically significant differences between the conditions for credibility, t(42) = 0.35, p 
= .72 or expectancy, t(42) = 0.39, p = .69. 
Treatment Attrition  
Of the 69 participants, 64 (92.8%) completed the intervention: 90.9% in the ACT+SSRI 
group, 86.4% in the CBT+SSRI group, and 100% in the continued SSRI group. There was no 
significant difference between the attrition rates in the ACT+SSRI and CBT+SSRI conditions 
(χ2(1) = 0.12, p = .73). The average attendance of sessions was 9.1 (1.1) out of 10 in the 
ACT+SSRI condition and 10.5 (1.8) out of 12 in the CBT+SSRI condition. 
Treatment Outcomes 
OCD symptoms. The MLM analysis of CY-BOCS total scores revealed a statistically 
significant main effect for condition, F(2, 57.02) = 11.55, p < .001, time, F(2, 111.90) = 127.12, 
p < .001, and time × condition interaction, F(4, 111.78) = 5.47, p < .001. Post hoc analyses 
indicated that CY-BOCS scores did not significantly differ in the ACT+SSRI and CBT+SSRI 
conditions across time (slope = -0.22, SE = 0.81), t(66.60) = -0.27, pholm = .79; however, both 
conditions demonstrated significantly lower CY-BOCS scores across time compared to the 
continued SSRI condition, CBT+SSRI: (slope = -3.05, SE = 0.78), t(64.83) = -3.92, pholm < .001, 
ACT: (slope = -3.27, SE = 0.77), t(63.71) = -4.24, pholm < .001. Comparisons of the CBT+SSRI 
and ACT+SSRI conditions revealed no significant differences at post-treatment, (slope = 0.40, 
SE = 1.16), t(165.47) = 0.35, pholm = 1.00 or follow-up, (slope = -0.25, SE = 1.25), t(172.03) = -
0.20, pholm = 1.00. 
Participants in the CBT+SSRI condition on average reported large, statistically 
significant reductions (33.3%) in CY-BOCS scores from pre- to post-treatment, t(39) = 7.22, p < 
ACT vs CBT vs Continued SSRI for Adolescent OCD   
 
16 
.001, g = 2.22 and large, statistically significant reductions (17.7%) from post-treatment to 
follow-up, t(33) = 3.23, p = .003, g = 1.07. Similarly, participants in the ACT+SSRI condition on 
average reported large, statistically significant reductions (29.4%) in CY-BOCS scores from pre- 
to post-treatment, t(40) = 5.69, p < .001, g = 1.72 and large, statistically significant reductions 
(21.8%) from post-treatment to follow-up, t(35) = 3.21, p = .003, g = 1.04. Finally, participants 
in the continued SSRI condition on average reported small, statistically nonsignificant reductions 
(15.2%) in CY-BOCS scores from pre- to post-treatment, t(48) = 0.88, p = .38, g = .25 and 
medium, statistically nonsignificant reductions (9.4%) from post-treatment to follow-up, t(45) = 
1.97, p = .055, g = 0.57. 
Depression symptoms. The MLM analysis of CDI total scores revealed no significant 
main effect for condition, F(2, 62.01) = 3.03, p = .055, a statistically significant main effects for 
time, F(2, 118.17) = 111.60, p < .001, and a statistically significant time × condition interaction, 
F(4, 118.05) = 5.42, p < .001. Post hoc analyses indicated that CDI scores did not significantly 
differ in the ACT+SSRI and CBT+SSRI conditions across time (slope = -0.61, SE = 0.62), 
t(66.19) = -0.99, pholm = .343. Additionally, neither the ACT+SSRI or CBT+SSRI condition 
demonstrated significantly lower CDI scores across time compared to the continued SSRI 
condition, CBT+SSRI: (slope = -.82, SE = 0.59), t(64.43) = -1.38, pholm = .343, ACT+SSRI: 
(slope = -1.44, SE = 0.59), t(63.32) = -2.44, pholm = .053. However, at follow-up, the ACT+SSRI 
condition demonstrated a statistically significant difference in CDI scores compared to the 
continued SSRI condition, (slope = -3.74, SE = 0.93), t(174.16) = -4.01, pholm = .001 while the 
CBT+SSRI condition did not, (slope = -2.23, SE = 0.95), t(174.67) = -2.35, pholm = .236. 
Participants in the CBT+SSRI condition on average reported large, statistically 
significant reductions (31.3%) in CDI scores from pre- to post-treatment, t(39) = 7.32, p < .001, 
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g = 2.25 and large, statistically significant reductions (20.1%) from post-treatment to follow-up, 
t(33) = 3.33, p = .002, g = 1.10. Similarly, participants in the ACT+SSRI condition on average 
reported large, statistically significant reductions (30.4%) in CDI scores from pre- to post-
treatment, t(40) = 5.42, p < .001, g = 1.64 and large, statistically significant reductions (32.2%) 
from post-treatment to follow-up, t(35) = 4.70, p < .001, g = 1.52. Finally, participants in the 
continued SSRI condition on average reported medium, statistically significant reductions 
(15.2%) in CDI scores from pre- to post-treatment, t(48) = 2.60, p = .012, g = .72 and medium, 
statistically significant reductions (13.2%) from post-treatment to follow-up, t(45) = 2.37, p = 
.022, g = 0.68. 
Valued Living. The MLM analysis of VLQ composite scores revealed a statistically 
significant main effect for condition, F(2, 65.87) = 18.72, p < .001, time, F(2, 121.72) = 6.74, p 
= .002, and time × condition interaction, F(4, 121.61) = 7.31, p < .001. Post hoc analyses 
indicated that VLQ scores significantly increased across time in the ACT+SSRI condition 
compared to the CBT+SSRI condition, (slope = 5.93, SE = 1.31), t(66.26) = 4.52, pholm < .001 
and continued SSRI condition, (slope = 7.28, SE = 1.24), t(63.38) = 5.86, pholm < .001; however 
no significant difference was demonstrated between the CBT+SSRI and continued SSRI 
condition, (slope = 1.35, SE = 1.25), t(64.50) = 1.08, pholm = .285. Comparisons of the 
CBT+SSRI and ACT+ SSRI conditions revealed significant differences at post-treatment, (slope 
= 8.86, SE = 1.94), t(170.68) = 4.56, pholm < .001 and follow-up, (slope = -0.25, SE = 1.25), 
t(172.03) = -0.20, pholm = 1.00. 
Participants in the CBT+SSRI condition on average reported statistically nonsignificant 
increases (3.5%) in VLQ scores from pre- to post-treatment, t(39) = 0.65, p = .521, g = .199 and 
statistically nonsignificant increases (1.3%) from post-treatment to follow-up, t(33) = 0.30, p = 
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.764, g = .101. Conversely, participants in the ACT+SSRI condition on average reported large, 
statistically significant increases (19.9%) in VLQ scores from pre- to post-treatment, t(40) = 
4.39, p < .001, g = 1.33 and statistically nonsignificant reductions (1.3%) from post-treatment to 
follow-up, t(35) = .33, p = .743, g = .107. Finally, participants in the continued SSRI condition 
on average reported statistically nonsignificant reductions (2.9%) in VLQ scores from pre- to 
post-treatment, t(48) = 0.59, p = .556, g = .165 and statistically nonsignificant reductions (2.0%) 
from post-treatment to follow-up, t(45) = .46, p = .647, g = 0.13. 
Psychological Flexibility. The MLM analysis of AFQ-Y8 composite scores revealed a 
statistically significant main effect for condition, F(2, 48.74) = 19.20, p < .001, time, F(2, 
104.33) = 40.70, p < .001, and time × condition interaction, F(4, 104.20) = 9.12, p < .001. Post 
hoc analyses indicated that AFQ-Y8 scores significantly decreased across time in the ACT+SSRI 
condition compared to the CBT+SSRI condition, (slope = -1.80, SE = .79), t(65.88) = -2.29, pholm 
= .026. Additionally, AFQ-Y8 scores in continued SSRI condition were significantly higher over 
time than the ACT+SSRI condition, (slope = -4.55, SE = .74), t(63.04) = -6.11, pholm < .001 and 
the CBT+SSRI condition, (slope = -2.75, SE = .75), t(64.14) = -3.65, pholm = .001. Comparisons 
of the CBT+SSRI and ACT+SSRI conditions indicated no significant differences at post-
treatment, (slope = -2.12, SE = 1.21), t(174.57) = -1.76, pholm = .885 or follow-up, (slope = -2.87, 
SE = 1.31), t(176.98) = -2.18, pholm = .445. 
Participants in the CBT+SSRI condition on average reported large, statistically 
significant decreases (27.2%) in AFQ-Y8 scores from pre- to post-treatment, t(39) = 3.89, p < 
.001, g = 1.20 and small, statistically nonsignificant decreases (9.9%) from post-treatment to 
follow-up, t(33) = 1.21, p = .236, g = .400. Conversely, participants in the ACT+SSRI condition 
on average reported large, statistically significant decreases (37.1%) in AFQ-Y8 scores from pre- 
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to post-treatment, t(40) = 5.72, p < .001, g = 1.73 and medium, statistically significant reductions 
(16.5%) from post-treatment to follow-up, t(35) = 2.05, p = .048, g = .662. Finally, participants 
in the continued SSRI condition on average reported statistically nonsignificant increases (4.4%) 
in AFQ-Y8 scores from pre- to post-treatment, t(48) = .67, p = .505, g = .187 and medium, 
statistically significant reductions (14.7%) from post-treatment to follow-up, t(45) = 2.40, p = 
.021, g = .689. 
Mindfulness. The MLM analysis of CAMM composite scores revealed a statistically 
significant main effect for condition, F(2, 61.12) = 42.43, p < .001, time, F(2, 120.51) = 6.08, p 
= .003, and time × condition interaction, F(4, 120.40) = 10.67, p < .001. Post hoc analyses 
indicated that CAMM scores significantly increased across time in the ACT+SSRI condition 
compared to the CBT+SSRI condition, (slope = 5.16, SE = .73), t(64.69) = 7.07, pholm < .001 and 
continued SSRI condition, (slope = 5.98, SE = .69), t(62.06) = 8.71, pholm < .001. However, 
CAMM scores in the CBT+SSRI condition did not significantly differ over time from the 
continued SSRI condition, (slope = .83, SE = .70), t(63.06) = 1.19, pholm = .237. Comparisons of 
the CBT+SSRI and ACT+SSRI conditions indicated significant differences at post-treatment, 
(slope = 4.40, SE = 1.24), t(178.99) = 3.55, pholm = .011 and follow-up, (slope = 10.16, SE = 
1.35), t(178.99) = 7.52, pholm < .001. 
Participants in the CBT+SSRI condition on average reported statistically nonsignificant 
increases (4.8%) in CAMM scores from pre- to post-treatment, t(39) = 1.08, p = .288, g = .331 
and statistically nonsignificant decreases (7.0%) from post-treatment to follow-up, t(33) = 1.46, p 
= .153, g = .485. Conversely, participants in the ACT+SSRI condition on average reported large, 
statistically significant increases (15.9%) in CAMM scores from pre- to post-treatment, t(40) = 
3.86, p < .001, g = 1.17 and large, statistically significant increases (12.0%) from post-treatment 
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to follow-up, t(35) = 3.34, p = .002, g = 1.08. Finally, participants in the continued SSRI 
condition on average reported statistically nonsignificant decreases (2.2%) in CAMM scores 
from pre- to post-treatment, t(48) = .41, p = .684, g = .114 and statistically nonsignificant 
reductions (3.7%) from post-treatment to follow-up, t(45) = .70, p = .490, g = .200. 
Discussion 
This study compared the effectiveness of ACT+SSRI, CBT+SSRI, or continued SSRI for 
adolescents (12-18 years of age) in Iran who were already receiving standard pharmacotherapy 
intervention. Results showed that ACT+SSRI and CBT+SSRI were equally effective at reducing 
OCD, as measured by the C-YBOCS at post-treatment and follow-up, and that they were more 
effective than continued medication. Additionally, drop-out was low in both active conditions: 
8.1% ACT+SSRI and 13.6% CBT+SSRI. As depression is commonly comorbid with OCD it 
was assessed in this study. Results showed that depression scores dropped significantly from pre- 
to post-treatment, and to follow-up in ACT+SSRI and CBT+SSRI. Only pre-treatment to 
followed decreases were seen in the continued SSRI condition. Three ACT–consistent process of 
change measures were utilized in this study. In AFQ-8, the ACT+SSRI condition saw large 
significant decreases from pre- to post-treatment and continued significant change to follow-up. 
The CBT+SSRI condition showed significant decreases from pre- to post-treatment. No 
significant changes were seen in the continued SSRI condition. In VLQ, ACT+SSRI caused a 
significant improvement in the composite score from the pre- to post-treatment and follow-up 
over CBT+SSRI and the continued SSRI condition. Similar results were found for mindfulness 
with ACT+SSRI showing greater positive changes over CBT+SSRI and the continued SSRI 
condition. However, this trend was not stable after three months of follow-up. According to the 
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CAMM results, ACT+SSRI led to a greater improvement than CBT+SSRI and the continued 
SSRI groups in at post-treatment and the 3-month follow-up.  
There are many clinical and empirical implications to this study. This study was the first 
RCT to examine ACT for adolescents with OCD. Results were consistent with a recently 
completed trial of exposure with response prevention (ERP) vs ACT+ERP for adults with OCD 
(Twohig et al, 2018). These studies showed strong and equivalent effects on OCD. Clinically, 
this suggests that while CBT is still the most supported intervention for adolescent OCD, that 
ACT can be a reasonable treatment option. This suggestion is also consistent with recent meta-
analyses of ACT and CBT for anxiety disorders (Bluett et al., 2014).  
A notable, and different finding is that the process of change measures all showed greater 
changes in ACT+SSRI than comparison conditions. All three process of change measures were 
consistent with the ACT model and not the purported processes of change in CBT. Nevertheless, 
the finding that psychological flexibility, values, and mindfulness changed more in ACT+SSRI 
than CBT+SSRI is notable. This is inconsistent with the recent trial of ACT+ERP vs ERP where 
no differences were seen between conditions (Twohig et al., 2018). Coupled with previous 
studies, this suggests that ACT and CBT for adolescent OCD may work through different and 
shared processes of change (Arch, Wolitzky-Taylor, Eifert, & Craske, 2012; Forman et al., 2012; 
Swain, Hancock, Hainsworth, & Bowman, 2015).  
Another interesting finding from this study is that ACT was useful without including in-
session exposure exercises. In the original ACT for OCD trail, ACT was done without in-session 
exposures to test whether it could be effective without already known effective procedures (i.e., 
exposure and response prevention). This was never meant to be the best clinical manner in which 
to implement ACT; rather, it was an experimental test. In ACT, exposure involves increasing the 
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person’s tendency for experiencing internal incidents as they are and performing behavioral 
commitment exercises that may necessarily include exposure to obsessive-compulsive situations 
outside of the sessions. Still, many researchers have continued to test that method of delivery and 
have found success (Twohig & Levin, 2017); although many others have also found 
implementing exposures from an ACT model to also be useful (e.g., Twohig et al., 2018).  
Another notable finding from this study is that ACT is useful with adolescents. The 
literature on ACT and adolescents lags greatly behind the literature on ACT with adults. There 
are many reasons for this, but some are concerned that ACT may be too complicated to teach to 
younger audiences. These findings suggest that ACT can successfully be taught to younger 
audiences and affect the wanted processes of change. After a recent RCT of ACT vs CBT for 
mixed anxiety disorders, this is the largest trial of ACT for adolescents ever completed (Hancock 
et al., 2016). This study greatly increases our data on the utility of ACT for younger populations.  
As with all studies, there are also limitations that should be addressed in future studies. 
First, all scales utilized in this study were originally developed for a western population. While 
many have been translated and validated for this population in this study, they will be less 
aligned than measures created for the target population. Second, the protocols used in this 
research did not involve the same number of sessions, and the CBT protocol (12 sessions) had 
two more sessions than ACT (10 sessions). In any case, the present study findings indicated the 
similar effectiveness of the two protocols. Third, the therapists’ allegiance was not assessed in 
this research, but therapists were involved in both intervention groups. They also had almost the 
same levels of experience of ACT and CBT and were supervised equally. Relatedly and fourth, 
treatment integrity was assessed for each therapy type (ACT and CBT), but therapy sessions 
were not assessed for crossover of techniques. Fifth, all participants entered the study on SSRIs. 
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While this is uncommon for a western RCT, this is a common occurrence in studies out of Iran 
where the full sample is already prescribed medication as part of the country’s medical practice 
(Rohani et al., 2018). This affects generalizability in that the effects should be seen as ACT or 
CBT plus SSRIs. Because the participants were on a stable dose prior to starting ACT or CBT, 
we can still see the comparative effects of those interventions  
In conclusion, this research provided evidence of ACT+SSRI as an effective treatment 
for adolescent OCD, even though it appears ACT+SSRI and CBT+SSRI are equally effective for 
the treatment of OCD in adolescents. Moreover, it seems ACT+SSRI can improve OCD without 
the need for the traditional exposure as this has been found in a handful of trials (e.g., Twohig et 
al. 2010), and thus it seems to be a proper alternative to the treatments for OCD in adolescents 
who do not respond to the exposure-based treatments. The present findings can pave the way for 
the future research and further development of ACT for children and adolescents with OCD. 
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Note. ACT = Acceptance and Commitment Therapy; AFQ-Y8 = Avoidance and Fusion 
Questionnaire for Youth; CAMM = Child and Adolescent Mindfulness Measure; CBT = 
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Cognitive Behavioral Therapy; CDI = Children's Depression Inventory; CY-BOCS = 
Children’s Yale-Brown Obsessive Compulsive Scale; VLQ = Valued Living Questionnaire. 
 
  




Means and Standard Deviations of Outcome Measures at Each Time-Point by Condition 



















































































































Note. ACT = Acceptance and Commitment Therapy; AFQ-Y8 = Avoidance and Fusion Questionnaire for Youth; CAMM = Child 
and Adolescent Mindfulness Measure; CBT = Cognitive Behavioral Therapy; Children’s Depression Inventory; CY-BOCS = 








Estimated Slopes, Standard Errors (SE), Degrees of Freedom (df), and Holm-Corrected p-Values from Pre- to Post-
Treatment and Post-Treatment to Follow-Up by Condition 
 ACT + SSRI CBT + SSRI Continued SSRI 
 Slope (SE) df p Slope (SE) df p Slope (SE) df p 
CY-BOCS          
     Pre-Post 6.95 (.98) 118.78 <.001 8.17 (1.00) 121.07 <.001 3.72 (.89) 114.51 .001 
     Post-FU 3.30 (1.05) 119.18 .028 2.64 (1.08) 119.45 .160 1.66 (.93) 118.19 .454 
CDI          
     Pre-Post 5.24 (.82) 119.12 <.001 5.55 (.83) 121.41 <.001 2.48 (.74) 114.84 .016 
     Post-FU 3.80 (.87) 120.07 <.001 2.30 (.90) 120.37 .153 1.72 (.77) 118.96 .275 
AFQ-Y8          
     Pre-Post 6.76 (1.09) 119.32 <.001 5.05 (1.10) 121.61 <.001 -.84 (.99) 115.09 1.00 
     Post-FU 2.08 (1.16) 120.68 .885 1.33 (1.20) 121.00 1.00 2.51 (1.03) 119.49 .260 
VLQ          
     Pre-Post -9.37 (1.70) 119.07 <.001 -1.26 (1.72) 121.36 1.00 1.08 (1.54) 114.79 1.00 
     Post-FU .38 (1.81) 119.93 1.00 -.29 (1.87) 120.22 1.00 .69 (1.61) 118.84 1.00 
CAMM          
     Pre-Post -4.68 (1.19) 119.94 .003 -1.19 (1.21) 122.08 1.00 .52 (1.09) 115.99 1.00 
     Post-FU -4.02 (1.27) 122.65 .044 1.73 (1.31) 123.03 1.00 .85 (1.13) 121.22 1.00 
Note. ACT = Acceptance and Commitment Therapy; AFQ-Y8 = Avoidance and Fusion Questionnaire for Youth; CAMM = 
Child and Adolescent Mindfulness Measure; CBT = Cognitive Behavioral Therapy; CDI = Children’s Depression Inventory; 
CY-BOCS = Children's Yale-Brown Obsessive Compulsive Scale; VLQ = Valued Living Questionnaire. 
 




Figure 1. Participant flowchart. 
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Figure 2. Results of multilevel modeling analyses. Estimated marginal means with standard error 
bars are displayed for primary outcomes by conditon at pre-treatment, post-treatment, and three-
month follow-up. 
